DNAtrix’s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating…
DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced that its lead product, DNX-2401, has been designated by the European…
Read More...
Read More...